Literature DB >> 6084771

Antiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol.

J J Lynch, D J Wilber, D G Montgomery, T M Hsieh, E Patterson, B R Lucchesi.   

Abstract

The electrocardiographic responses to programmed ventricular stimulation and acute posterolateral myocardial ischemia were studied in conscious dogs treated with the resolved optical isomers of sotalol. Studies were conducted 3-7 days after anterior myocardial infarction to determine the relative contributions of beta-adrenergic receptor blockade and direct Class III electrophysiologic actions in the antiarrhythmic and antifibrillatory actions of the isomers. With cumulative i.v. administration of up to 8 mg/kg, both the beta-blocking levorotatory isomer and the dextrorotatory isomer suppressed the induction of ventricular tachyarrhythmias by programmed stimulation in at least 50% of dogs tested. Both isomers produced equivalent 15-20% increases in normal zone ventricular refractoriness, thereby preventing propagation of programmed ventricular extrastimuli of sufficient prematurity to elicit tachyarrhythmias. The levorotatory isomer of sotalol prolonged the PR interval; the administration of the dextrorotatory isomer increased QTc and, in several dogs, was associated with the development of ventricular ectopy. The prior administration of 8 mg/kg of either optical isomer of sotalol prevented the immediate spontaneous development of ventricular fibrillation in response to ischemia at a distance from the previous site of infarction. These results suggest that alterations in ventricular refractoriness may underlie the antiarrhythmic and antifibrillatory actions of the optical isomers of sotalol and of racemic sotalol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084771

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  Actions and mechanisms of action of novel analogues of sotalol on guinea-pig and rabbit ventricular cells.

Authors:  S P Connors; E W Gill; D A Terrar
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  Evidence for inhibition by ICS 205-930 and stimulation by BRL 34915 of K+ conductance in cardiac muscle.

Authors:  G Scholtysik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

Review 3.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes.

Authors:  H Nakaya; N Tohse; Y Takeda; M Kanno
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Anion and cation modulation of the guinea-pig ventricular action potential during beta-adrenoceptor stimulation.

Authors:  P C Levesque; C D Clark; S I Zakarov; L V Rosenshtraukh; J R Hume
Journal:  Pflugers Arch       Date:  1993-06       Impact factor: 3.657

6.  Hemodynamic effects of the D- and L-isomers of sotalol on normal myocardium.

Authors:  H M Hoffmeister; M Beyer; L Seipel
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

7.  Cellular electrophysiological effects of D- and DL-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity.

Authors:  T J Campbell
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

8.  Antifibrillatory effects of clofilium in the rabbit isolated heart.

Authors:  G S Friedrichs; L Chi; A L Green; B R Lucchesi
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

Review 9.  Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.

Authors:  S V Advani; B N Singh
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

10.  The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.

Authors:  J M Poirier; P Jaillon; B Lecocq; V Lecocq; A Ferry; G Cheymol
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.